Cancer development in various organs, including the breast, ovary, brain, bladder, colon,
and lung, is frequently connected to disturbances in the epidermal growth factor receptor …

Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that has been approved for
metastatic non-small cell lung cancer and highly aggressive pancreatic cancer. Although …

Erlotinib is a reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
that acts by inhibiting signaling pathways, resulting in the disruption of cancerous cell …

Erlotinib (ELB) is a tyrosine kinase inhibitor that targets the activity of Epidermal Growth
Factor Receptor (EGFR) protein found in both healthy and cancerous cells. It binds …

Erlotinib is a tyrosine kinase inhibitor and it can treat tumors, such as pancreatic and locally
advanced lung cancer or metastatic cancer. The traditional formulation of erlotinib currently …

Comprehensive understanding of signaling pathways regulating cancer progression has led
to tremendous advances of molecularly targeted therapies. The epidermal growth factor …

Epidermal growth factor receptor (EGFR) plays a key role in signal transduction pathways
associated with cell proliferation, growth, and survival. Its overexpression and aberrant …

As active targeting using nanomedicines establishes itself as a strategy of choice in cancer
therapy, several target receptors or ligands overexpressed in cancer cells have been …

Oral tyrosine kinase inhibitors (TKIs) against epidermal growth factor receptor (EGFR) family
have been introduced into the clinic to treat human malignancies for decades. Despite …

Inhibitors of epidermal growth factor (EGF) receptor (EGFR) tyrosine kinases show efficacy
in cancers that are highly addicted to nonmutated EGF signaling, but off-target effects limit …